SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on September 22, 2003; DOI 10.1182/blood-2003-03-0954. This Article Full Text (PDF) All Versions of this Article: 2003-03-0954v1 103/3/1037    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Cathcart, K. Articles by Scheinberg, D. A Search for Related Content PubMed PubMed Citation Articles by Cathcart, K. Articles by Scheinberg, D. A Social Bookmarking                   What's this? Submitted March 27, 2003 Accepted August 17, 2003 A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia Kathleen Cathcart, Javier Pinilla-Ibarz, Tatyana Korontsvit, Joseph Schwartz, Victoriya Zakhaleva, Esperanza B Papadopoulus, and David A Scheinberg* Department of Medicine and Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY, USA * Corresponding author; email: d-scheinberg{at}ski.mskcc.org. A tumor specific, bcr-abl derived fusion peptide vaccine can be safely administered to patients with CML and can elicit a bcr-abl peptide specific T cell immune response (Blood 95: 1781, 2000). In the present phase II trial, 14 patients with CML in chronic phase were vaccinated with 6 fusion peptides mixed with QS-21. No significant toxic effects were observed. Fourteen of 14 patients had DTH and/or CD4 proliferative responses develop after beginning vaccinations, and 11 of 14 patients showed gamma-IFN release by CD4 ELISPOT at one or more timepoints. These responses were CD4/CD45RO+. A peptide specific CD8+ interferon gamma ELISPOT was found in 4 patients. Four patients in hematologic remission had a decrease in Ph percentage (three concurrently receiving alpha-interferon and one on Imatinib), and three patients in molecular relapse after allogenic transplant became transiently PCR negative after vaccination; two of these patients received concurrent DLI. All 5 patients on IFN ultimately reached a complete cytogenetic remission. In conclusion, a tumor-specific bcr-abl breakpoint peptide-derived vaccine can be safely administered and can reliably elicit measurable peptide specific CD4 immune responses, including in patients post bone marrow transplantation, on interferon or on Imatinib. A relationship between the clinical responses and vaccination cannot be determined from this trial. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: V. T. Ho, M. Vanneman, H. Kim, T. Sasada, Y. J. Kang, M. Pasek, C. Cutler, J. Koreth, E. Alyea, S. Sarantopoulos, et al. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation PNAS, September 15, 2009; 106(37): 15825 - 15830. [Abstract] [Full Text] [PDF] O. Bohana-Kashtan, S. Morisot, R. Hildreth, C. Brayton, H. I. Levitsky, and C. I. Civin Selective Reduction of Graft-versus-Host Disease-Mediating Human T Cells by Ex Vivo Treatment with Soluble Fas Ligand J. Immunol., July 1, 2009; 183(1): 696 - 705. [Abstract] [Full Text] [PDF] J. Greiner, L. Bullinger, B.-a. Guinn, H. Dohner, and M. Schmitt Leukemia-Associated Antigens Are Critical for the Proliferation of Acute Myeloid Leukemia Cells Clin. Cancer Res., November 15, 2008; 14(22): 7161 - 7166. [Abstract] [Full Text] [PDF] C. I-U. Chen, H. T. Maecker, and P. P. Lee Development and dynamics of robust T-cell responses to CML under imatinib treatment Blood, June 1, 2008; 111(11): 5342 - 5349. [Abstract] [Full Text] [PDF] A. J. Barrett Leukemia Vaccines to Boost the Graft-versus-Leukemia Effect after Allogeneic Stem Cell Transplantation ASCO Educational Book, January 1, 2008; 2008(1): 330 - 333. [Abstract] [Full Text] [PDF] F. Scheich, J. Duyster, C. Peschel, and H. Bernhard The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens Blood, October 1, 2007; 110(7): 2556 - 2560. [Abstract] [Full Text] [PDF] G. Volpe, A. Cignetti, C. Panuzzo, M. Kuka, K. Vitaggio, M. Brancaccio, G. Perrone, M. Rinaldi, G. Prato, M. Fava, et al. Alternative BCR/ABL Splice Variants in Philadelphia Chromosome-Positive Leukemias Result in Novel Tumor-Specific Fusion Proteins that May Represent Potential Targets for Immunotherapy Approaches Cancer Res., June 1, 2007; 67(11): 5300 - 5307. [Abstract] [Full Text] [PDF] A. Quintas-Cardama and J. E. Cortes Chronic Myeloid Leukemia: Diagnosis and Treatment Mayo Clin. Proc., July 1, 2006; 81(7): 973 - 988. [Abstract] [Full Text] [PDF] F. Grunebach, V. Mirakaj, V. Mirakaj, M. R. Muller, T. Brummendorf, and P. Brossart BCR-ABL Is Not an Immunodominant Antigen in Chronic Myelogenous Leukemia Cancer Res., June 1, 2006; 66(11): 5892 - 5900. [Abstract] [Full Text] [PDF] J. Cortes and H. Kantarjian New Targeted Approaches in Chronic Myeloid Leukemia J. Clin. Oncol., September 10, 2005; 23(26): 6316 - 6324. [Abstract] [Full Text] [PDF] M. Gannage, M. Abel, A.-S. Michallet, S. Delluc, M. Lambert, S. Giraudier, R. Kratzer, G. Niedermann, L. Saveanu, F. Guilhot, et al. Ex Vivo Characterization of Multiepitopic Tumor-Specific CD8 T Cells in Patients with Chronic Myeloid Leukemia: Implications for Vaccine Development and Adoptive Cellular Immunotherapy J. Immunol., June 15, 2005; 174(12): 8210 - 8218. [Abstract] [Full Text] [PDF] Z. Li, Y. Qiao, B. Liu, E. J. Laska, P. Chakravarthi, J. M. Kulko, R. D. Bona, M. Fang, U. Hegde, V. Moyo, et al. Combination of Imatinib Mesylate with Autologous Leukocyte-Derived Heat Shock Protein and Chronic Myelogenous Leukemia Clin. Cancer Res., June 15, 2005; 11(12): 4460 - 4468. [Abstract] [Full Text] [PDF] Y. Zeng, M. W. Graner, S. Thompson, M. Marron, and E. Katsanis Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells Blood, March 1, 2005; 105(5): 2016 - 2022. [Abstract] [Full Text] [PDF] N. M. Butt, L. Wang, H. M. Abu-Eisha, S. E. Christmas, and R. E. Clark BCR-ABL-specific T cells can be detected in healthy donors and in chronic myeloid leukemia patients following allogeneic stem cell transplantation Blood, April 15, 2004; 103(8): 3245 - 3245. [Full Text] [PDF] M. A. Caligiuri, A. Velardi, D. A. Scheinberg, and I. M. Borrello Immunotherapeutic Approaches for Hematologic Malignancies Hematology, January 1, 2004; 2004(1): 337 - 353. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020